Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial
- 31 October 2010
- journal article
- research article
- Published by Elsevier BV in Urology
- Vol. 76 (4), 923-926
- https://doi.org/10.1016/j.urology.2010.04.025
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial TractJournal of Clinical Oncology, 2009
- Combination of antiangiogenesis with chemotherapy for more effective cancer treatmentMolecular Cancer Therapeutics, 2008
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206Journal of Clinical Oncology, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progressionUrologic Oncology: Seminars and Original Investigations, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Tumour angiogenesis: pathophysiology and clinical significanceThe Netherlands Journal of Medicine, 1996